SCHEMBL7609562

SCHEMBL7609562

O=C(O)CCC(OP(=O)(O)Cc1ccccn1)C(=O)O.O=C(O)CCC(OP(=O)(O)Cc1cccnc1)C(=O)O

nearest known ligand 0.41

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
FOLH1 Q04609 1/20 0.39
TBXAS1 P24557 9/20 0.39
ANPEP P15144 1/20 0.38
ERAP2 Q6P179 1/20 0.38
ERAP1 Q9NZ08 1/20 0.38
HTT P42858 1/20 0.38
NAPRT Q6XQN6 1/20 0.37
FDPS P14324 2/20 0.37
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5060524 0.91 TBXAS1 (0.46) FOLH1TBXAS1ANPEPERAP2ERAP1
SCHEMBL1377622 0.89 ALDH1A1 (0.43) CYP1A2FOLH1FDPS
SCHEMBL1377537 0.80 FOLH1 (0.52) CYP1A2CYP2D6FOLH1
SCHEMBL5059776 0.80 TBXAS1 (0.50) TBXAS1ANPEPERAP2ERAP1NAPRT
SCHEMBL5057928 0.80 ANPEP (0.52) TBXAS1ANPEPERAP2ERAP1NAPRT
SCHEMBL5057902 0.79 TBXAS1 (0.55) TBXAS1ANPEPERAP2ERAP1
SCHEMBL7606078 0.79 SMN1; SMN2 (0.41) CYP1A2FOLH1FDPS
SCHEMBL5052953 0.78 FDPS (0.51) CYP1A2CYP2D6FDPS
SCHEMBL5054254 0.78 ANPEP (0.47) TBXAS1ANPEPERAP2ERAP1FDPS
SCHEMBL2368223 0.77 SMN1; SMN2 (0.42) CYP1A2CYP2D6FDPSKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2002515040-A 2002-05-21 JP claimed
EP-0954295-A1 METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1999-11-10 EP claimed
WO-1997048409-A1 METHODS OF CANCER TREATMENT USING NAALADASE INHIBITORS GUILFORD PHARMACEUTICALS INC. (US) 1997-12-24 WO claimed